• Actinogen secures second tranche of $4.3m in non-dilutive funding
• Funding to be used for ongoing XanaMIA Alzheimer's disease trial and general working capital
• Reaffirms cash runway out to mid-2026

Actinogen Medical has announced that it has secured a second tranche of $4.3m in non-dilutive funding from Endpoints Capital under a funding facility of up to $13.8m. The funds will be used to support the ongoing XanaMIA phase 2b/3 Alzheimer's disease trial, which has now fully enrolled 220 patients across 35 sites in Australia and the US, as well as for general working capital. The Australian Government's Research and Development Tax Incentive (RDTI) program provides eligible companies with a rebate against R&D-related expenditure, and this funding from Endpoints is secured against Actinogen's forecast FY26 RDTI rebate. Actinogen's Chief Financial Officer, Will Souter, stated that the funding further strengthens the company's balance sheet as it approaches the interim analysis for the XanaMIA trial, which is expected in late January 2026, and the final topline results in November 2026. The company also plans to commence the open-label extension (OLE) of the XanaMIA trial in the current quarter.